Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fujian Guangshengtang Pharmaceutical is a leading Chinese pharmaceutical company specializing in the research, development, and commercialization of anti-viral drugs, particularly for liver diseases. The company is well-known for its comprehensive portfolio of nucleoside analogue drugs for chronic Hepatitis B, including entecavir and tenofovir. Beyond hepatology, Guangshengtang has expanded its R&D efforts into innovative treatments for COVID-19, non-alcoholic steatohepatitis (NASH), and oncology. Headquartered in Fujian, China, the company is listed on the Shenzhen Stock Exchange and maintains a strong focus on providing affordable, high-quality medications to the domestic market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fujian Guangshengtang Pharmaceutical.